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Background: HIV/AIDS is one of twenty first century’s challenges to human being with protean manifestation
affecting nearly all organs of our body. It is causing high morbidity and mortality especially in sub-Saharan Africa
with numerous ocular complications and blindness. The purpose of this study was to determine the patterns of
ocular manifestations of HIV/AIDS and their correlation with CD4+Tcells count.
Methods: A cross-sectional study was done on 348 HIV-positive patients presented to Anti-Retroviral Therapy
clinics. Data were collected using face-to-face interview, clinical examination and laboratory investigation, and
analyzed using SPSS version 13 software. Statistical association test was done and p<0.05 was considered
significant. Other statistical tests like student t-test and logistic regression were also done.
Results: Of 348 patients, 175 were on antiretroviral therapy and 173 were not on therapy. The mean duration of
therapy was 27 months. The overall prevalence of ocular manifestations was 25.3%. The commonest ocular
manifestation was keratoconjunctivitis sicca (11.3%) followed by blepharitis (3.2%), molluscum contagiosum (2.6%),
conjunctival squamous cell carcinoma (2.3%), conjunctival microvasculopathy (2.3%), cranial nerve palsies (2%),
herpes zoster ophthalmicus (HZO) (1.2%), and HIV retinopathy (0.6%). HIV retinopathy and conjunctival
microvasculopathy were common in patient with CD4+ count of <200 cells/μl while HZO and molluscum
contagiosum were common in patients with CD4+ count of 200–499 cells/μl. Prevalence of ocular manifestation
was higher among patients on HAART (32.6%) than those patients not on HAART (17.9%) (p<0.05). There was
statistically significant association between ocular manifestation and sex, CD4+Tcells count, and age (p<0.05).
CD4+ count, <200 cells/μl and age >35 years were independent risk factors for ocular manifestations.
Conclusion: The study showed that the prevalence of ocular manifestation of HIV/AIDS is lower than previous
studies and could be due to antiretroviral therapy. Lower CD4 count is a risk as well as predictor for ocular
manifestations.
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Human Immunodeficiency Virus (HIV) and Acquired Im-
munodeficiency Syndrome (AIDS) have been a major public
health problem since the first case report in 1980s, and two
third of people living with HIV/AIDS live in Sub-Saharan
Africa [1]. Even though the prevalence of HIV/AIDS in
Ethiopia is declining [2,3], it is still the major public health
problem with a prevalence of 2.3% [4]. The disease is having
a diverse impact on human being: affecting the economy,
social life, education and the health of people. Patients with
HIV/AIDS suffer from wide varieties of complications that
are related to the infection. No organ of the body is spared
from the virus or related diseases. The eye is an organ with
wide spectrum HIV-related manifestations. The ocular man-
ifestations can be the presenting sign of a systemic infection
in an otherwise asymptomatic HIV-positive person. The dis-
ease can have adnexal, anterior segment, posterior segment,
orbital, and neuroophthalmic manifestations [5]. Blindness,
due to HIV-related complications, is also one of the prob-
lems endangering the life of people living with HIV with
prevalence ranging from 6.9%-23% [6,7]. The prevalence of
HIV-related ocular manifestations increase as CD4+ T cells
count decreases. Diseases like cytomegalovirus (CMV) retin-
itis, keratoconjunctival sicca, retinal and conjunctival
microvasculopathy occur commonly when the CD4 cells
count falls below 100 cells/mm3 and Kaposi’s sarcoma oc-
curs when the CD4+T cells count falls below 500 cells/mm3
[8]. Introduction of highly active anti-retroviral therapy
(HAART) has changed the prevalence and pattern of HIV-
related ocular manifestation [9]. Before the introduction of
HAART, CMV retinitis was the commonest ocular mani-
festation affecting 30%-40% of HIV-infected individuals
[5,10]. In the HAART era, it has been suggested that there
has been an estimated 80% decrease in the incidence of
CMV retinitis [10]. The incidence of Kaposi’s sarcoma has
declined by an estimated 87% [11]. Retinal microvas-
culopathy and opportunistic retinal infections were also
found to be lower [9,12]. In the HAART era clinical entities
like immune recovery uveitis have appeared as a cause of
concern related to blindness [10,13].
Only few studies were done in Ethiopia and the major-
ity of these studies were in the pre-HAART era (before
2002) and the study population was symptomatic pa-
tients with advanced stage of the disease and hence
doesn’t reflect the true picture of HIV-related ocular
manifestation among HIV-positive in the presence of
anti-retroviral therapy. The purpose of this study is,
therefore, to describe the prevalence and pattern of ocu-
lar manifestation among HIV/AIDS patients and deter-
mine correlation with the CD4+T cell count.
Methods
A cross-sectional study was conducted at two Anti-
Retroviral Therapy (ART) clinics (Jimma UniversitySpecialized Hospital and Jimma health center) from
October to November 2009. From a total of 5692 adult
HIV/AIDS patients, a sample of 369 was taken using 95%
CI using simple random sampling technique. Only adults
were included in the study because of consent issues.
Proportionate numbers of patients were selected from the
two ARTcenters and 185 patients were taken from those on
Highly Active Anti-Retroviral Therapy (HAART) and 184
patients from those not on HAART. Patients with additional
medical problems like Diabetes mellitus, hypertension and
ocular trauma, which can have overlapping manifestation
with HIV/AIDS, were excluded from the study.
Data were collected using interview, clinical examin-
ation and laboratory investigation. Questionnaire and re-
cording format were used for the interview and recording
clinical examination findings. Before the actual data were
collected, a pretest was done on 37 (10%) study subjects.
The interview was conducted by trained ophthalmic
nurses. Eye examinations included; best corrected visual
acuity test, intraocular pressure measurement, adnexal
examination, pupil, motility, alignment, anterior segment,
dilated fundus examination, and cranial nerve function
tests. All ophthalmic examinations were done by investiga-
tors. The following tools were used for ophthalmic exami-
nations; Snellen visual acuity charts, Schiotz tonometer,
indirect ophthalmoscope, slit lamp biomicroscope, 20D
Volk lens, 90D Volk lens, and Goldmann three-mirror
lens. To prevent cross contamination, the instruments
were irrigated with tap water and then disinfected by
soaking in absolute alcohol for 10 minutes and rinsed with
tap water and allowed to dry for 10 minutes after each
procedure. For dilated fundus examination 1% tropicamide
with or without phenylephrine was used and to anaesthetize
the surface of the eye during intraocular pressure measure-
ment and gonioscopy, 1% tetracaine eye drop was used. For
some patients, based on their clinical finding, toxoplasmosis
and syphilis serology tests were done. Histopathologic tech-
nique was used to confirm cases of tumor. For all patients
who did not have CD4+ T cell count within three months
before data collection, CD4 count was done during the study
and 238 had new CD4+ Tcells count.
Data were analyzed using SPSS version 13 software.
X2-test was used to see association and p<0.05 was con-
sidered significant. Other statistical tests like student t-test
and logistic regression were also used to see associations
and differences between variables.
The study was conducted following Helsinki declar-
ation and after it was approved by the Ethical Commit-
tee of Jimma University. Informed consent was taken
and only those who consented were studied.
Results
Out of 369 sampled study subjects, 348 patients were
studied with the response rate of 94%. The mean age of
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(216) of patients were in the age group of 20–34 years.
The majority of the patients (74.1%) seen were female.
One hundred seventy five patients were on HAART and
the rest (173) were not on HAART. The mean duration
of HAART was 27 months (SD ± 16.2, range 1–74).
Of the 348 patients, 88 (25.3%) had ocular manifest-
ation. The prevalence of ocular manifestation in males
(33.3%) was higher than the prevalence in females
(23.3%) and this difference was statistically significant
(p<0.05) (Table 1). Ocular manifestation was common in
the age group of 30–34 years (20.7%) followed by 25–
29 years (19.5%), and 35–39 years (18.4%). However, this
difference in distribution of ocular manifestation in dif-
ferent age groups was not statistically significant
(p>0.05) (Table 1). The mean age of patients with ocular
manifestation (33.92±9.5 years) was higher than the
mean age of patients without ocular manifestation (31.2±
8.7 years) and this difference was statistically significant
(t=2.463, p<0.05).
The mean CD4+ T cells count for those patients on
HAART and those who were not on HAART were
366.85 cells/ml (SD±236.58) and 367.59 (SD±218.25) re-
spectively. This mean difference was not statistically sig-
nificant (t=−0.030; p=0.117). Prevalence of ocular
manifestation was higher among patients on HAART
(32.6%) than among patients not on HAART (17.9%)
(p<0.05). But there was no statistically significant differ-
ence existed for patients with lower CD4+ cells count
whether they were on HAART or not (p=0.099).
Patients with ocular manifestation had less CD4+ T
cells count compared to patients without ocular mani-
festation with mean CD4+ T cell count of 308.74 cells/
μl, and 386.56 cells/μl respectively and this was a statisti-
cally significant difference (t=−2.736; p=0.007). Patients
with CD4+T cell count of <200 cells/μl comprised 36.5%Table 1 Distribution of demographic characteristics and








Sex Male 30 (33.3) 60 (67.7) 0.041
Female 58 (22.5) 200 (75.5)
Total 88 (25.3) 260 (74.7)
Age <20 2 (2.3) 8 (3.1) 0.23
20-24 11 (12.5) 50 (19.2)
25-29 17 (19.3) 62 (23.8)
30-34 18 (20.5) 58 (22.3)
35-39 17 (19.3) 35 (13.5)
40-44 10 (11.4) 28 (10.8)
>45 13 (14.8) 19 (7.3)
Total 88 (25.3) 260 (74.7)of patients with ocular manifestation and only 18.7%
of patients without ocular manifestation were in this
CD4+T cell count category (Table 2).
Logistic regression was done with variables which had
significant association with the presence of ocular mani-
festation. Male patients were 1.75 times more likely to
have ocular manifestation compared to female patients
and this was statistically significant (p<0.05; CI: 1.03-2.96).
But when controlled for age and CD4+ T cell count, this
was not statistically significant (OR (CI) =1.37(0.77-2.41),
P>0.05). Patients of age >35 years old were 1.86 more
likely to have ocular manifestation compared to patients
of age ≤ 35 years old and it was statistically significant
(p<0.027; CI: (1.07-2.30)). The odds of having ocular
manifestation was 2.52 for patients with CD4+ T cells
count less than 200 cells/μl compared to patients with a
CD4+ T cell count of ≥200 cells/μl and it was statistically
significant (p=001; CI: 1.45-4.38). Patients on ART were
1.86 times more likely to have ocular manifestation com-
pared to those who were not on ART and it was statisti-
cally significant (p<0.05; CI: 1.10-3.13) (Table 3).
Adnexal manifestation was seen in 44 (12.8%) patients.
The commonest adnexal manifestation was blepharitis
which was seen in 3.2% patients. Molluscum contagiosum,
conjunctival squamous cell carcinoma and conjunctival
microvasculopathy were seen in 2.6%, 2.3%, and 2.3% re-
spectively (Table 4). Majority of patients with adnexal
manifestation (48.8%) had CD4+ T cell count of < 200
cells/μl whereas 80.8% patients with no adnexal manifest-
ation had CD4+ T cells count of >200 μl. Conjunctival
microvasculopathy and conjunctival squamous cell carcin-
oma were common in patients with a CD4+ T cell count
of <200 cells/μl. Molluscum contagiosum and herpes zos-
ter ophthalmicus were common in patients with a CD4+
T cell count of 200–499 cells/μl (Table 4).
Forty three (12.3%) patients had anterior segment
manifestations; the commonest manifestation being Ker-
atoconjunctivitis sicca which was seen in 11.5% of all pa-
tients. Only 2 (0.6%), and 1(0.3%) patients had infectious
keratitis and uveitis respectively (Table 5). No statisti-
cally significant difference was seen in the distribution of
anterior segment manifestation and CD4+ T cell count
(p>0.05). Keratoconjunctivitis sicca was seen commonly
in patients with a CD4+ T cell count of 200–499 cells/μl
(42.6%) (Table 5).
Posterior segment and neuro-ophthalmic manifestations
were not common. Only 16 (5%) patients had either pos-
terior segment or neuro-ophthalmic manifestations. Facial
nerve palsy was seen in 6 (1.8%) patients and it was com-
mon in patients with a CD4+ T cell count of ≥200 cells/μl
(Table 6). All patients with HIV retinopathy had CD4+ T
cell count of <200 cells/μl. Toxoplasmosis retinocho-
roiditis was seen in patients with a CD4+ T cell count of
200–499 cells/μl.
Table 2 Ocular manifestation and CD4+ T cell count among HIV/AIDS patients, Jimma, Ethiopia
Ocular manifestation CD4+ T cell count (cells/μl) Total n (%) p-value
0-199 n (%) 200-499 n (%) 500+ n (%)
Yes 31 (36.5) 36 (42.4) 18 (21.2) 85 (25.3) 0.002
No 47 (18.7) 139 (55.4) 65 (25.9) 251 (74.7)
Total 78 (23.2) 174 (52.1) 83 (24.7) 336 (100.0)
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>6/18 in either or both eyes. No patient was found to be
bilaterally blind but 9 patients (2.6%) had monocular
blindness (Table 7). Half of the monocular blindness was
due to refractive error and only two patients had mon-
ocular blindness secondary to central retinal vein occlu-
sion and toxoplasmosis retinochoroiditis.
Discussion
In this study, there was no record of WHO stage of the
HIV/AIDS the study subjects and hence this information
was not included in the analysis though we compared
our findings with other studies. However, this will not
have significant influence on the interpretation as the
CD4+ T cell count is used as part of the parameter for
staging and found to be correlated with WHO stage of
HIV/AIDS [14].
The prevalence of ocular manifestation in this study
was found to be 25.3% which is much lower than the
study conducted in Gondar University Hospital [15]
which was 60% but comparable to other studies in
Africa (19% and 20%) [16,17]. This difference could be
due to the nature of the study at Gondar which was
conducted on patients who were admitted to hospital
with a medical problem and came to the eye clinic with
ocular complaint and 90% of patients were in WHO
stage of III and IV. The fact that the Gondar study was
conducted during the pre-HAART era might have con-
tributed to the difference as it is known that HAARTTable 3 Risk factors for ocular manifestation of HIV/AIDS amo
Factors Ocular manifestation
Yes, n (%) No, n (%)
Sex§ Male 30 (33.3) 60 (65.9)
Female 58 (22.5) 200 (77.5)
Ageɸ >35 years 35 (34.3) 67 (65.7)
≤35 years 53 (21.5) 193 (78.5)
CD4+T cell count‡ <200 cells/μl 31 (39.7) 47 (60.3)
≥200 cells/μl 54 (20.9) 204 (79.1)
HAARTʈ Yes 57 (32.6) 118 (67.4)
No 31 (17.9)) 142 (82.1)
§; adjusted for age and CD4+ cell count.
ɸ; adjusted for sex and CD4+ cell count.
ʈ; adjusted for age and sex.
‡; adjusted for age, sex, and CD4+ cells count.decreases the prevalence of HIV/AIDS related ocular
diseases.
In this study, it was found that the mean CD4+ T cells
count of patients with ocular manifestation (308.74
cells/μl) was lower than the mean CD4+ T cell count of
patients without ocular manifestation (386.56 cells/μl). It
was also found that ocular manifestation was common
in patients with a CD4+ T cell count of <200 cells/μl.
These findings are similar to other studies conducted in
India [7] and Senegal [18]. There was, however, one pe-
culiar finding in our study. Patients who were on
HAART had a high prevalence of ocular manifestation
compared to those who were not on HAART. This
could be due to the low CD4+ T cells count during the
initiation of HAART as patients with a CD4+ T cell
count of <250 cells/μl are put on HAART. This low
CD4 count is associated with higher prevalence of ocular
manifestation as shown in this study and patients might
have already developed the manifestation before initi-
ation of HAART. Even though patients are on HAART
and their CD+T cells count increases, the newly formed
population of lymphocytes are not associated with func-
tional maturity of the immune system and patients are
not protected [8,19]. Our patients were on HAART for
an average of 27 months and this is not enough for the
functional maturity of the immune system as shown by
Pakker et ai [20] that at around two years only a small
proportion of individuals demonstrate immune reconsti-
tution close to the normal range.ng patients Jimma, Ethiopia
OR (unadjusted) (95% CI) OR (adjusted) (95% CI) P-value
1.72 (1.02-2.92) 1.36 (0.77-2.39) 0.295
1
1.90 (1.14-3.16) 1.86 (1.07-2.30) 0.027
1
2.49 (1.45-4.29) 2.52 (1.45-4.38) 0.001
1
2.21 (1.34-3.65) 1.86 (1.10-3.13) 0.020
1
Table 4 Distribution of adnexal manifestation and CD4+
T cell count of the study subjects Jimma town, Ethiopia
Adnexal manifestation CD4+ T cell count Total
0-199 200-499 500+ n (%)
n (%) n (%) n (%)
Blepharitis 2 (18.2) 4 (36.4) 5 (45.4) 11 (3.2)
Molluscum contagiosum 3 (33.3) 5 (55.6) 1 (11.1) 9 (2.6)
CV 7 (87.5) 1 (12.5) 0 (0) 8 (2.3)
Conjunctival SCC* 6 (75) 2 (25) 0 (0) 8 (2.3)
HZO 1 (33.3) 2 (66.7) 0 (0) 3 (0.9)
Kaposi of lid 1 (100) 0 (0) 0 (0) 1 (0.3)
Kaposi of conjunctiva 0 (0) 0 (0) 1 (100) 1 (0.3)
Others 1 (50) 0 (0) 1 (50) 2 (0.6)
Total 21 (48.8) 14 (32.6) 8 (18.6) 43 (12.8)
*SCC= squamous cell carcinoma.
*HZO= herpes zoster ophthalmicus.
*CV= conjunctival microvasculopathy.
Table 6 Neuro-ophthalmic and posterior segment




CD4+ T cell count Total
n(%)
0-199 n(%) 200-499 n(%) >500 n(%)
Facial nerve palsy 1 (20) 2 (40) 2 (40) 5 (1.5)
Optic neuritis or atrophy 1 (25) 2 (50) 1 (25) 4 (1.2)
Chorioretinal pigmented scar 1 (33.3) 2 (66.7) 0 (0) 3 (0.9)
Toxoplasmosis
retinochoroiditis
0 (0) 1 (100) 0 (0) 1 (0.3)
HIV retinopathy 2 (100) 0 (0) 0 (0) 2 (0.6)
Cytomegal virus retinitis 0 (0) 0 (0) 0 (0) 0 (0)
Total 5 (1.5) 7 (2.0) 3 (0.9) 15 (4.5)
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cell count of <200 cells/μl were independent risk factors
for patients to develop ocular manifestations. CD4+ T cell
count <200 cells/μl being a risk factor is a well-established
fact [7,18] and the difference between the different age
group could be due to the effects of age on the immunity
of the patients.
The commonest ocular manifestations in this study were
adnexal (12.8%) of which blepharitis was the commonest
(3.2%) followed by molluscum contagiosum (2.6%), con-
junctival Squamous cell carcinoma (2.3%) and conjunctival
microvasculopathy (2.3%). This finding is different from
the study conducted in Gondar University hospital [15]
where the commonest ocular manifestations were HIV
retinopathy (24%) followed by neuro-ophthalmic disorders
(9.6%). This could be due to the fact that the study was
done on patients with advanced stage of the disease (90%
in stage III and IV) where HIV retinopathy and neuro-
ophthalmic disorders are common. The distribution of ad-
nexal manifestation with CD4+ T cell count is nearly
similar to earlier studies [5,18] whereby Molluscum
contagiosum and herpes zoster ophthalmicus occurred inTable 5 Anterior segment ocular manifestations with
CD4+ T cell count, Jimma, Ethiopia
Anterior segment
manifestations
CD4+ T cell count Total n (%)
0-199 200-499 500+
n (%) n (%) n (%)
KCS* 9 (23.7) 20 (52.6) 9 (23.7) 38 (11.3)
Infectious Keratitis 0 (.0) 1 (50.0) 1 (50.0) 2 (0.6)
Uveitis 1 (100.0) 0 (0) 0 (0) 1 (0.3)
Total 10 (2.9) 21 (6.3) 10 (2.9) 4 1(12.2)
* KCS= Keratoconjunctivitis sicca.CD4+ T cell count range of 200–499 cells/μl and conjunc-
tival microvasculopathy occurred in patients with a CD4+
T cell count of <200 cells/μl.
The commonest anterior segment manifestation was
Keratoconjunctivitis sicca (11.5%). The prevalence is
similar to another study (10%-20%) [21].
Neuro-ophthalmic manifestations were seen in 2.6% of
all patients which is lower than the finding of the Gondar
study (9.6%) [15]. HIV retinopathy was seen in only 2
(0.6%) patients which is very much lower than previous
studies (24%-40%) [15,22,23]. Other studies in Gambia
(3%) [23] and India (5%) [6] showed reasonably lower
prevalence of HIV retinopathy compared to the above
studies, but still higher than this study. The studies with
higher prevalence of HIV retinopathy were done on pa-
tients in the Pre-HAART era and majority of the study
subjects were in advanced stages of the disease. HIV retin-
opathy was seen solely in patients with a CD4+ T cell
count of <200 cells/μl and toxoplasmosis retinochoroiditis
was seen in patients with a CD4+ T cell count of 200–499
cells/μl and this is similar to other studies [5,18]. There
was no single case of CMV retinitis in this study. It was
also found by other studies that CMV retinitis is rare
among African patients [12,24,25]. This could be the rea-
son for the low prevalence of immune recovery uveitis
(0.3%) despite 50% of our study patients being on HAART.
Conclusion
The overall prevalence of ocular manifestation of HIV/
AIDS was lower than what is reported in previousTable 7 Distribution of visual acuity of study population,
Jimma, Ethiopia
Visual acuity Right eye n (%) Left eye n (%) Both eyes n (%)
<3/60 1 (0.3) 8 (2.3) 0 (0)
3/60-6/60 8 (2.3) 2. (0.6) 2 (0.6)
6/60-6/18 6 (1.7) 7 (2) 4 (1.2)
>6/18 333 (95.7) 331( 95.1) 331 (97.2)
Total 348 (100) 348 (100) 337 (100)
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higher among male patients, patients with lower CD4+
T cell count and older patients. The commonest ocular
manifestations were anterior segment and adnexal mani-
festations. Posterior segment manifestations were rare
and there was no case of CMV retinitis. Age >35 years,
and CD4+ T cell count of <200 cells/μl were found to
be independent risk factors for developing ocular
manifestations.
Though ocular manifestations of HIV/AIDS are low,
HIV/AIDS patients especially those with lower CD4+ T
cell count and older patients should have eye checkup
and follow up by an ophthalmologist; and there should
be concerted care with a multidisciplinary approach.
Further prospective study should be carried out to inves-
tigate why some ocular findings are rare in our setting
so that the real clinical picture and possible reasons will
be known. The association between age and ocular
manifestation warrants further investigation.
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